Mirtazapina Qualigen (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Qualigen, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Qualigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance, regulatory compliance and reliable logistics where required, ensuring consistent product availability across multiple regions to meet timely delivery.

Mirtazapine, a NaSSA antidepressant, is used primarily in the management of depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Depressive episodes in bipolar I disorder (adjunct therapy): helps alleviate the depressive phase when combined with a mood stabilizer. - Depression associated with chronic medical conditions: supports mood improvement in patients with comorbid illnesses such as cancer or chronic pain.

Mirtazapine may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or worsening depression - Severe hypersensitivity reactions (e.g., anaphylaxis)

When prescribing mirtazapine, clinicians should observe several safety considerations. - Assess hepatic function: adjust dose in patients with severe liver impairment. - Monitor body weight: due to potential appetite increase and weight gain. - Evaluate for suicidal ideation: especially during the initial treatment period. - Use caution in elderly patients: increased risk of sedation, falls, and confusion. - Avoid abrupt discontinuation: taper gradually under medical supervision to reduce withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use may cause hypertensive crisis or serotonin syndrome. - Linezolid or other reversible MAO inhibitors: risk of severe serotonin toxicity. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): may increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Anticoagulants (e.g., warfarin): possible alteration of INR, requiring monitoring.